Search Results 21-30 of 149 for ⚠【아시아365.COM / 가입코드GK】 올킬티비주소 판도라가입 판도라주소 판도라먹튀 판도라검증 그랜드가입⚠

  1. Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma - Mayo Clinic

    Romidepsin and lenalidomide may stop the growth of cancer cells by blocking enzymes needed for cell growth. Giving rituximab together with romidepsin and ...

  2. Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant - Mayo Clinic

    Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunosuppressive therapy, such as dexamethasone, may ...

  3. Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract - Mayo Clinic

    About this study. This study will evaluate the effect of presatovir on respiratory syncytial virus (RSV) viral load in autologous or allogeneic ...

  4. Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia - Mayo Clinic

    This phase II trial studies how well daunorubicin hydrochloride, cytarabine, and nilotinib work in treating patients newly diagnosed with acute myeloid leukemia ...

  5. A Study to Evaluate if Benralizumab Compared to Mepolizumab May be Beneficial in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) - Mayo Clinic

    Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

  6. Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors - Mayo Clinic

    Pazopanib hydrochloride may prevent the growth of new blood vessels that tumors need to grow. Studying samples of blood in the laboratory from patients ...

  7. Program to Evaluate Tulisokibart for Moderate to Severe Crohn’s Disease - Mayo Clinic

    Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

  8. https://www.mayoclinic.org/spanish_patient_consumer_faq.xml

    ... url><url><loc>https://www.mayoclinic.org/es/diseases-conditions/multiple-sclerosis/expert-answers/acetyl-l-carnitine/faq-20057801</loc><lastmod>2024-09 ...

  9. A Study to Evaluate Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients with Chronic Myeloid Leukemia and Persistently- Detectable Minimal Residual Disease - Mayo Clinic

    Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of cancer cells to grow and spread. Dasatinib, imatinib mesylate, and nilotinib may ...

  10. Phase 1 Study to Evaluate the Safety of ATA188 in Subjects With Progressive and Relapsing-Remitting Multiple Sclerosis - Mayo Clinic

    Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...